Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies

 
• By Sten Stovall
T cells
Syncona founded Quell Therapeutics with £35m Series A Financing • Source: Shutterstock

More from Business

More from Scrip